Trethera Corporation and Nanotherapeutics Sign Exclusive Worldwide Agreement for Rights to Triapine® in Hematological Malignancies

Santa Monica, CA and Alachua, FL, January 5, 2017 – Trethera Corporation and Nanotherapeutics, Inc. today announced the signing of an exclusive worldwide agreement whereby Nanotherapeutics has granted Trethera an exclusive license for the global development, manufacturing and marketing of Triapine® (3-AP) and all formulations, for the treatment of hematological malignancies. Triapine® is a clinical-stage, small molecule inhibitor of ribonucleotide reductase (RNR), a key enzyme in the de novo pathway of nucleotide biosynthesis.

Read full press release